Compositions and methods for treating cancer

Patent metadata

Field	Value
Publication number	US-11578136-B2
Application number	US-201816477506-A
Country	US
Kind code	B2
Filing date	Mar 16, 2018
Priority date	Mar 16, 2017
Publication date	Feb 14, 2023
Grant date	Feb 14, 2023

Abstract

The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

First claim

The invention claimed is:

1. An antibody or antibody fragment that binds and inhibits the ATPase activity of a soluble extracellular domain human CD39 (NTPDasel) protein, wherein the antibody or antibody fragment comprises:
(a) a HCDR1 comprising the amino acid sequence DYNMH (SEQ ID NO: 8); a HCDR2 comprising the amino acid sequence YIVPLNGGSTFNQKFKG (SEQ ID NO: 9); a HCDR3 comprising the amino acid sequence GGTRFAY (SEQ ID NO: 10; a LCDR1 comprising the amino acid sequence RASESVDNFGVSFMY (SEQ ID NO: 11); a LCDR2 region comprising the amino acid sequence GASNQGS (SEQ ID NO: 12); and a LCDR3 region comprising the amino acid sequence QQTKEVPYT (SEQ ID NO: 13);
(b) a HCDR1 comprising the amino acid sequence DYNMH (SEQ ID NO: 16); a HCDR2 comprising the amino acid sequence YINPNNGGTTYNQKFKG (SEQ ID NO: 17); a HCDR3 comprising the amino acid sequence GGTRFAS (SEQ ID NO: 18; a LCDR1 comprising the amino acid sequence RASESVDNYGISFMY (SEQ ID NO: 19); a LCDR2 region comprising the amino acid sequence AASTQGS (SEQ ID NO: 20); and a LCDR3 region comprising the amino acid sequence QQSKEVPFT (SEQ ID NO: 21);
(c) a HCDR1 comprising the amino acid sequence DTYIN (SEQ ID NO: 24); a HCDR2 comprising the amino acid sequence RIDPANGNTKYDPKFQG (SEQ ID NO: 25); a HCDR3 comprising the amino acid sequence WGYDDEEADYFDS (SEQ ID NO: 26); a LCDR1 comprising the amino acid sequence RASESVDNYGISFMN (SEQ ID NO: 27); a LCDR2 region comprising the amino acid sequence AASNQGS (SEQ ID NO: 28); and a LCDR3 region comprising the amino acid sequence HQSKEVPWT (SEQ ID NO: 29); or
(d) a HCDR1 comprising the amino acid sequence SFWMN (SEQ ID NO: 32); a HCDR2 comprising the amino acid sequence EIDPSDFYTNSNQRFKG (SEQ ID NO: 33); a HCDR3 comprising the amino acid sequence GDFGWYFDV (SEQ ID NO: 34); a LCDR1 comprising the amino acid sequence SASSSINSNYLH (SEQ ID NO: 35); a LCDR2 region comprising the amino acid sequence RTSNLAS (SEQ ID NO: 36); and a LCDR3 region comprising the amino acid sequence QQGSSLPRT (SEQ ID NO: 37).

2. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment inhibits the ATPase activity of the CD39 protein in the presence of exogenously added ATP at a concentration of 20 μM.

3. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment is capable of binding human CD39 protein at the surface of a cell and that is capable of inhibiting the ATPase activity of said CD39 protein at the surface of a cell.

4. The antibody or antibody fragment of claim 1 , wherein the soluble extracellular domain CD39 is a CD39 protein lacking the transmembrane domains near the N- and C-terminal ends found in membrane bound CD39.

5. The antibody or antibody fragment of claim 1 , wherein the antibody comprises an Fc domain comprising an amino acid modification compared to a wild-type Fc domain, and that has reduced or abolished binding to one or more, or all of, the human Fcγ receptors CD16A, CD16B, CD32A, CD32B and/or CD64.

6. A pharmaceutical composition comprising an antibody or antibody fragment according to claim 1 , and a pharmaceutically acceptable carrier.

7. A nucleic acid encoding a heavy and/or light chain of an antibody or antibody fragment of claim 1 .

8. A recombinant host cell producing the antibody or antibody fragment of claim 1 .

9. A method for the treatment of a tumor or cancer in an individual in need thereof, the method comprising administering to the individual an effective amount of an antibody or antibody fragment of claim 1 .

10. The method of claim 9 , wherein the method comprises administering to said individual an effective amount of an antibody or antibody fragment of claim 1 , in combination with an antibody that neutralizes the inhibitory activity of human PD-1.

11. The method of claim 9 , wherein the tumor or cancer is a leukemia, bladder cancer, glioma, glioblastoma, ovarian cancer, melanoma, prostate cancer, thyroid cancer, esophageal cancer or a breast cancer.

12. A method for reducing the ATPase activity of soluble CD39 protein in an individual, the method comprising administering to said individual an effective amount of an antibody or antibody fragment of claim 1 .

Assignees

• Innate Pharma
• Orega Biotech

Inventors

• Chanteux Stéphanie
• Gourdin Nicolas
• Paturel Carine
• Perrot Ivan
• Rossi Benjamin

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/41

  Glycosylation, sialylation, or fucosylation · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• G01N33/6872

  Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title